Fluidigm (FLDM) Reports Prelim. 1Q Revenues Below Consensus; Withdraws FY20 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
Fluidigm Provides Update on COVID-19 Impact and Preliminary Revenue Estimate for First Quarter 2020
April 14, 2020 4:05 PM EDTSOUTH SAN FRANCISCO, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today provided an update on the impact of the COVID-19 pandemic on its business and announced preliminary revenue estimates for the quarter ended March 31, 2020.
Fluidigm has been actively responding to the pandemic by protecting our employees and serving urgent customer needs while managing our liquidity.
Protecting our EmployeesAs Fluidigm is a designated essential business, our... More
